AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
testosterone propionate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| androgens/anabolic steroids | 4146 | 57-85-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An ester of TESTOSTERONE with a propionate substitution at the 17-beta position.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 4 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.988 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.481 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 50.933 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 121.339 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 1.230 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.780 | % | High | 1 |
| herg | hERG pIC50 | 4.867 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 65.464 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 84.918 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 1.220 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 20 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.235 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 362.243 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 1.760 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.454 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 2.920 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 263.027 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 16.040 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 2.050 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1.879 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 2, 1974 | FDA | WATSON LABS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug abuse | 85.54 | 67.98 | 26 | 134 | 104745 | 42516430 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug abuse | 97.97 | 76.26 | 26 | 126 | 177385 | 110411762 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA CS | M0001109 | Androstanes |
| FDA MoA | N0000000146 | Androgen Receptor Agonists |
| MeSH PA | D000728 | Androgens |
| MeSH PA | D006728 | Hormones |
| FDA EPC | N0000175824 | Androgen |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:50113 | androgen |
| CHEBI has role | CHEBI:50779 | appetite enhancer |
| CHEBI has role | CHEBI:50864 | insulin-sensitizing drug |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:83056 | <em>Daphnia magna</em> metabolite |
| CHEBI has role | CHEBI:176497 | geroprotector |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Deficiency of testosterone biosynthesis | indication | 38825009 | |
| Male hypogonadism | indication | 48723006 | |
| Undescended testicle | indication | 204878001 | DOID:11383 |
| Delayed puberty | indication | 400003000 | |
| Klinefelter's syndrome, XXY | indication | 405769009 | |
| Hormone receptor positive malignant neoplasm of breast | indication | 417181009 | |
| LHRH Deficiency | indication | ||
| Gynecomastia | contraindication | 4754008 | DOID:12698 |
| Hypercholesterolemia | contraindication | 13644009 | |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Chronic heart failure | contraindication | 48447003 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Edema | contraindication | 267038008 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Breast Carcinoma in Males | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | To increase rate of weight gain | Indication |
| Cattle | To improve feed efficiency | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Synovex H | Zoetis Inc. | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Androgen receptor | Nuclear hormone receptor | AGONIST | Ki | 9.60 | CHEMBL | CHEMBL | |||
| Steroid 17-alpha-hydroxylase/17,20 lyase | Enzyme | IC50 | 7.25 | CHEMBL | |||||
| Androgen receptor | Transcription factor | IC50 | 5.72 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017481 | VUID |
| N0000145869 | NUI |
| D00959 | KEGG_DRUG |
| 4017481 | VANDF |
| 4017484 | VANDF |
| C0039607 | UMLSCUI |
| CHEBI:9466 | CHEBI |
| TES | PDB_CHEM_ID |
| CHEMBL1170 | ChEMBL_ID |
| D043343 | MESH_DESCRIPTOR_UI |
| DB01420 | DRUGBANK_ID |
| 7100 | IUPHAR_LIGAND_ID |
| WI93Z9138A | UNII |
| 5995 | PUBCHEM_CID |
| DB00624 | DRUGBANK_ID |
| 10379 | RXNORM |
| 2966 | MMSL |
| 3050 | MMSL |
| 5552 | MMSL |
| 5555 | MMSL |
| d00558 | MMSL |
| 001245 | NDDF |
| 001248 | NDDF |
| 109033004 | SNOMEDCT_US |
| 43688007 | SNOMEDCT_US |
| 96338002 | SNOMEDCT_US |
| C0039601 | UMLSCUI |
| 6013 | PUBCHEM_CID |
| 1900 | INN_ID |
| D013739 | MESH_DESCRIPTOR_UI |
| CHEBI:17347 | CHEBI |
| WI93Z9138A | INXIGHT DRUGS |
Pharmaceutical products:
None